KF1601

KF1601 is a novel, orally bioavailable small molecule tyrosine kinase inhibitor developed for the treatment of chronic myeloid leukemia (CML), particularly targeting cases with resistance to existing therapies. It acts as a dual inhibitor of BCR::ABL1—including the T315I mutation—and FLT3 kinases. Preclinical studies have demonstrated that KF1601 effectively inhibits both BCR::ABL signaling (even in T315I-mutant forms associated with drug resistance) and FLT3 signaling implicated in blast phase CML progression. In animal models, it achieved complete tumor regression and prolonged survival without inducing severe thrombo-inflammatory side effects seen with some other TKIs like ponatinib. The drug is being developed by ImmunoForge and has received IND approval for clinical trials in Korea[3][4][5][6][8].

Other names

Benzamide, N-[3-(1-cyano-1-methylethyl)-5-(4-methyl-1H-imidazol-1-yl)phenyl]-2-fluoro-4-methyl-5-[2-[8-[(1-methyl-1H-pyrazol-4-yl)amino]imidazo[1,2-a]pyridin-3-yl]ethynyl]-N-(3-(2-cyanopropan-2-yl)-5-(4-methyl-imidazol-l-yI)phenyl)-2-fluoro–4-methyl–5–((8–(l–methyl-lH-pyrazol–4-yI)amino)imidazo[ l, 2-a ]pyridin–3-yI )ethynyl )benzamide